IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
IGM Biosciences, Inc. (Nasdaq: IGMS) announced that CEO Fred Schwarzer will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will be webcast live and available for replay on the company's website for 90 days.
02/01/2024 - 07:00 AM
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations . A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc. www.igmbio.com .
Contact: igmbio@argotpartners.com
When and where will CEO Fred Schwarzer participate in a fireside chat?
CEO Fred Schwarzer will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024, at 2:30 p.m. EST in New York.
Where can I watch the live webcast of the event?
The live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations.
How long will the replay of the webcast be available?
A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
IGMS Rankings
#5303 Ranked by Stock Gains
IGMS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
United States
City
Mountain View
About IGMS
igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci
